NVC-001 is designed to target the mechanobiological root cause of LMNA dilated cardiomyopathy and has disease-modifying potential SINGAPORE, PARIS and PHILADELPHIA, Oct. 8, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company pioneering mechanobiology-targeted therapies designed to address the root causes of life-threatening cardiomyopathies, today announced that the first...
JINAN, China, May 30, 2026 /PRNewswire/ -- From May 25 to 29, 2026, the 7th China–CEEC Local Leaders' Meeting and 2026 Shandong International Friendship...